Table 2.

Selected studies of children and adolescents with PMBCL

Reference	Study type	Treatment	N	EFS, %
30	Prospective, subgroup analysis pooled data from 3 studies	NHL-BFM 86, 90, 95	28	70 (5 y)
31	Prospective, subgroup analysis	FAB/LMB 96	42	66 (5 y)
32	Prospective phase 2	DA-EPOCH-R	40	69 (2 y)
29	Retrospective	DA-EPOCH-R	38	81 (3 y)

EFS, event-free survival.